~~<i id='203D992DE5'><strike id='203D992DE5'><tt id='203D992DE5'><pre id='203D992DE5'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

knowledge

author：knowledge 2025-09-06 01:58:17 - browse：6667

Eli Lilly said Friday that it will acquire Dermira, a small biotech developing drugs for chronic skin conditions, for $1.1 billion.

The centerpiece of the deal is the Dermira drug called lebrikizumab that aims to treat people suffering from moderate-to-severe atopic dermatitis, the most common form of eczema, a disease characterized by inflamed, itchy, and scaly skin.

Phase 3 clinical trials of lebrikizumab in atopic dermatitis are underway. If successful, the drug could compete against Dupixent, which has grown into a commercial blockbuster for Regeneron Pharmaceuticals and Sanofi.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Novo: Oral version of Ozempic leads to 15% weight loss

hotspot

leisure time

focus

explore

entertainment

1:29PoliceandanimalcontrolofficersinEdwardsville,Kansas,workedtogetherwiththeBonnerSpringsPoliceDepa

WSS

A public health expert passes on football's full body collisions for youths

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

Flu vaccine reformulation won't be easy, manufacturers warn

Inside the rise of 'mukbang' eating videos

Reanimated hearts work just as well for transplants, study finds

Flu vaccine reformulation won't be easy, manufacturers warn

hotspot

knowledge

hotspot

Malaria cases in Florida and Texas: Here’s what you need to know

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

Drug repurposing or repositioning? The language matters

To bolster infectious disease surveillance, genomics powerhouses team up

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Immunocompromised patients offer clues on chronic Covid

23andMe had bad news about my health. I wish a person had delivered it

Altering the blood type of lungs raises potential for universal organs for transplants

Duchenne breakthrough therapy leaves behind pioneering families

Maisha Meds is a PBM, but don't call it that

hotspot

Reanimated hearts work just as well for transplants, study finds

Maisha Meds is a PBM, but don't call it that

Medicare drug price lawsuits could be good politics for Biden

Inside the rise of 'mukbang' eating videos

Immunocompromised patients offer clues on chronic Covid

Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

leisure time

focus

explore

entertainment